Funding: The American Migraine Prevalence and Prevention (AMPP) Study was funded through a research grant to the National Headache Foundation (NHF) from McNeil-Janssen Scientific Affairs (MJSA) LLC, Raritan, NJ. The AMPP Study database was donated by MJSA to the NHF for use in various projects. Additional funding for this manuscript was provided by Merck & Co. (Kenilworth, NJ) and CoLucid Pharmaceuticals (Cambridge, MA), now a wholly owned subsidiary of Eli Lilly and Company (Indianapolis, IN).
Conflict of Interest: Richard B. Lipton, MD, is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the National Institutes of Health (NIH): 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society (AHS), Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy's Laboratories/Promius Pharma, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff's Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa.
Michael L. Reed, PhD, is managing director of Vedanta Research, which has received support funded by Allergan, Amgen, Colucid Pharmaceuticals, Endo Pharmaceuticals, GlaxoSmithKline, Merck, Novartis, Ortho-McNeil, Teva Pharmaceuticals, Zogenix, and Dr. Reddy's Laboratories/Promius Pharma via grants from the NHF.
Tobias Kurth, MD, ScD, has received grants from the Else-Kröner-Fresenius-Stiftung/German Scholars Organization, the US NIH, and the French National Research Agency. He is a consultant for Amgen on a scientific project, for which the Charité - Universitätsmedizin Berlin receives research funds. He has received honoraria for editorial services from The British Medical Journal (BMJ) and Cephalalgia. As a board of trustee member of the International Headache Society (IHS), he has received compensation of travel and accommodation expenses by the IHS.
Kristina Fanning, PhD, is an employee of Vedanta Research, which has received support funded by Allergan, Amgen, Colucid Pharmaceuticals, Endo Pharmaceuticals, GlaxoSmithKline, Merck, Novartis, Ortho-McNeil, Teva Pharmaceuticals, Zogenix, and Dr. Reddy's Laboratories/Promius Pharma via grants from the NHF.
Dawn C. Buse, PhD, has received grant support and honoraria from Allergan, Amgen, Avanir, Biohaven, Eli Lilly, Dr. Reddy's Laboratories/Promius Pharma, the AHS, and the NHF. She is an employee of Montefiore Medical Center, which has received research support funded by Allergan, Amgen, Avanir, CoLucid Pharmaceuticals, Dr. Reddy's Laboratories/Promius Pharma, Teva Pharmaceuticals, and Zogenix, both directly and via grants to the NHF. She is on the editorial board of the Journal of Headache and Pain, Current Pain and Headache Reports, and Pain Pathways Magazine.